Role of radiotherapy in the treatment of -mutant non-small-cell lung cancer: a narrative review.

The emergence of targeted therapies, such as epidermal growth factor receptor () and anaplastic lymphoma kinase inhibitors, has marked a new chapter in the management of non-small-cell lung cancer (NSCLC). However, monotherapy with targeted agents often falls short in achieving optimal outcomes. The addition of radiotherapy (RT) has been shown to enhance therapeutic efficacy in various clinical settings. The LAURA trial (consolidation osimertinib) and POLESTAR trial (consolidation aumolertinib) suggest that targeted consolidation therapy following chemoradiotherapy is a promising approach for Stage III unresectable -mutant NSCLC. The integration of radiation with targeted therapies, while promising, is complex and requires ongoing research and multidisciplinary efforts to optimize patient outcomes. This review examines the role of radiotherapy in treating -mutant NSCLC across various stages, highlighting the significance of minimal residual disease and circulating tumor DNA, and identifies key challenges for advancing the field.